Equities

Qilian International Holding Group Ltd

BGM:NAQ

Qilian International Holding Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)8.08
  • Today's Change0.08 / 1.00%
  • Shares traded6.75k
  • 1 Year change+99.83%
  • Beta1.3863
Data delayed at least 15 minutes, as of Sep 19 2024 20:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Qilian International Holding Group Ltd's revenues fell -28.35% from 64.86m to 46.47m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 1.08m to a loss of 7.78m.
Gross margin2.92%
Net profit margin-27.56%
Operating margin-11.72%
Return on assets-14.43%
Return on equity-16.33%
Return on investment-17.01%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Qilian International Holding Group Ltd fell by 7.50m. However, the company earned 312.21k from its operations for a Cash Flow Margin of 0.67%. In addition the company used 4.74m on investing activities and also paid 2.92m in financing cash flows.
Cash flow per share-0.9427
Price/Cash flow per share--
Book value per share6.07
Tangible book value per share5.60
More ▼

Balance sheet in USDView more

Qilian International Holding Group Ltd uses little or no debt in its capital structure.
Current ratio7.05
Quick ratio6.06
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -822.62%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-629.64
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.